Kazuyoshi Takeda Selected Research

Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)

4/2014	Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.
3/2014	A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
4/2013	Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.
10/2012	Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazuyoshi Takeda Research Topics

Disease

80	Neoplasms (Cancer) 01/2022 - 01/2002
25	Neoplasm Metastasis (Metastasis) 01/2019 - 01/2002
8	Testicular Neoplasms (Testicular Cancer) 01/2018 - 07/2012
6	Carcinoma (Carcinomatosis) 01/2017 - 01/2005
5	Inflammation (Inflammations) 01/2020 - 04/2003
5	Breast Neoplasms (Breast Cancer) 01/2019 - 08/2008
4	Lung Neoplasms (Lung Cancer) 01/2022 - 04/2013
4	Melanoma (Melanoma, Malignant) 01/2017 - 01/2002
3	Esophageal Neoplasms (Esophageal Cancer) 01/2022 - 07/2012
3	Renal Cell Carcinoma (Grawitz Tumor) 01/2017 - 04/2008
3	Colorectal Neoplasms (Colorectal Cancer) 01/2016 - 03/2013
3	Colitis 03/2015 - 05/2011
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2014 - 11/2013
2	Schizophrenia (Dementia Praecox) 01/2018 - 01/2017
2	Cognitive Dysfunction 01/2018 - 01/2016
2	Fibrosarcoma 01/2017 - 06/2006
2	Hypoxia (Hypoxemia) 01/2017 - 01/2014
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 03/2015 - 05/2011
2	Esophageal Squamous Cell Carcinoma 04/2014 - 07/2012
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 03/2014 - 04/2013
2	Disease Progression 11/2013 - 04/2013
1	Neoplasm Micrometastasis 01/2022
1	Ischemia 01/2021
1	Reperfusion Injury 01/2021
1	Lymphocytosis 12/2018
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2018
1	Leukemia 12/2018
1	Philadelphia Chromosome 12/2018
1	Virus Diseases (Viral Diseases) 05/2018
1	Poliomyelitis (Polio) 01/2018

Drug/Important Bio-Agent (IBA)

19	Peptides (Polypeptides)IBA 01/2022 - 09/2010
18	AntigensIBA 01/2022 - 01/2002
16	CytokinesIBA 01/2020 - 02/2002
15	Monoclonal AntibodiesIBA 01/2022 - 01/2002
15	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2015 - 01/2002
12	LigandsIBA 09/2015 - 01/2002
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2010
11	EpitopesIBA 01/2018 - 09/2010
10	Protein Subunit VaccinesIBA 01/2022 - 09/2010
9	TNF-Related Apoptosis-Inducing LigandIBA 01/2020 - 02/2002
9	AntibodiesIBA 01/2018 - 01/2002
8	InterferonsIBA 12/2017 - 01/2002
7	VaccinesIBA 01/2022 - 09/2010
7	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 01/2020 - 02/2004
7	alpha-galactosylceramideIBA 08/2008 - 02/2002
5	Cancer VaccinesIBA 01/2022 - 07/2012
5	Messenger RNA (mRNA)IBA 01/2019 - 07/2012
5	Interleukin-12 (IL 12)IBA 12/2017 - 01/2002
5	PerforinIBA 12/2014 - 01/2002
5	HLA-A Antigens (HLA-A)IBA 03/2014 - 10/2012
4	Therapeutic UsesIBA 01/2022 - 01/2005
4	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2017
4	Fc Receptors (Fc Receptor)IBA 10/2017 - 02/2004
4	CarcinogensIBA 05/2015 - 01/2002
4	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 04/2014 - 10/2012
4	Insulin-Like Growth Factor II (Somatomedin A)IBA 04/2014 - 07/2012
4	KinesinsIBA 01/2014 - 01/2012
4	Fas Ligand Protein (Fas Ligand)IBA 09/2010 - 02/2002
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 10/2012
3	Interleukin-2 (IL2)IBA 01/2020 - 04/2008
3	Neutralizing AntibodiesIBA 01/2018 - 12/2008
3	MethylcholanthreneIBA 01/2017 - 01/2002
3	Death Domain ReceptorsIBA 02/2016 - 10/2004
3	Carrier Proteins (Binding Protein)IBA 04/2014 - 04/2013
3	Protein Kinases (Protein Kinase)IBA 04/2014 - 07/2012
3	Complementary DNA (cDNA)IBA 09/2010 - 01/2002
3	interleukin-21 (interleukin 21)IBA 04/2008 - 05/2006
2	Karyopherins (Importin)IBA 01/2020 - 12/2011
2	Pharmaceutical PreparationsIBA 01/2020 - 03/2003
2	Cadherins (E-Cadherin)IBA 01/2019 - 01/2012
2	Interleukin-10 (Interleukin 10)IBA 01/2018 - 05/2012
2	Natural Killer Cell ReceptorsIBA 12/2017 - 01/2009
2	Oncogene Proteins (Oncogene Protein)IBA 01/2017 - 07/2012
2	DNA (Deoxyribonucleic Acid)IBA 02/2016 - 12/2008
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016 - 09/2015
2	ChemokinesIBA 09/2015 - 03/2015
2	Dextran SulfateIBA 03/2015 - 01/2012
2	Peptide Hydrolases (Proteases)FDA Link 03/2015 - 04/2010
2	Gemcitabine FDA Link 01/2014 - 11/2013
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 11/2013 - 03/2013
2	1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)IBA 04/2013 - 07/2012
2	Neoplasm Antigens (Tumor Antigens)IBA 03/2013 - 09/2007
2	Interleukin-18 (Interleukin 18)IBA 04/2003 - 02/2002
2	Interferon-gamma (Interferon, gamma)IBA 02/2002 - 01/2002
1	B7-H1 AntigenIBA 01/2022
1	Thymic Stromal LymphopoietinIBA 01/2020
1	atelocollagenIBA 01/2020
1	importazoleIBA 01/2020
1	Carcinoembryonic AntigenIBA 01/2019
1	Cell Adhesion MoleculesIBA 01/2019
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2019
1	Chemokine CXCL12IBA 01/2019
1	Dasatinib (BMS 354825)FDA Link 12/2018
1	Propolis (Bee Bread)IBA 05/2018

Therapy/Procedure

37	Therapeutics 01/2022 - 11/2002
21	Immunotherapy 01/2021 - 01/2002
13	Drug Therapy (Chemotherapy) 05/2018 - 01/2007
3	Radiotherapy 01/2014 - 01/2007
2	Ligation 05/2015 - 08/2008
1	Liver Transplantation 01/2021